Atropos Health and Databricks Partner to Revolutionize Healthcare Data Sharing

Atropos Health, a company specializing in translating real-world clinical data into actionable evidence, has announced a strategic partnership with data intelligence and AI provider Databricks. This collaboration marks a significant step forward in healthcare data utilization, combining Atropos Health's expertise in real-world evidence generation with Databricks' advanced data intelligence capabilities.

The partnership leverages Databricks' delta sharing technology, an open-source approach that enables customers to share live data across platforms, clouds, and regions while maintaining security and governance. Through this integration, Atropos Health can access and link datasets across its extensive network, which encompasses more than 300 million patient records, including comprehensive oncology data.

By expanding on the Databricks Data Intelligence Platform, the collaboration aims to empower clinicians and researchers to create actionable insights that could accelerate drug discoveries and significantly reduce the time from symptom to treatment. The partnership brings together GENEVA OS (generative evidence acceleration operating system) and the Atropos evidence network, creating a powerful combination of real-world evidence and data intelligence services.

"Atropos Health exemplifies the transformative potential of building on Databricks, and it's incredible to watch its adoption among healthcare and life sciences organizations who are excited to harness the full power of their data," said Michael Sanky, vice president of Healthcare and Life Sciences GTM at Databricks.

This partnership represents the latest in a series of strategic collaborations for Atropos Health. In April, the company partnered with Ontada, a McKesson business focused on community oncology, to strengthen use cases for designing care protocols and promoting precision medicine. February saw a partnership with Emory Healthcare, where the health system piloted a program allowing clinical questions to be answered in real time using Atropos' platform. The company also established partnerships with xCures in January to leverage RWE-based insights for patient care, and with Merck to generate rapid insights and analytics based on real-world data.

The collaboration comes at a time of significant growth for both companies. Databricks recently achieved a $62 billion valuation after raising $10 billion in a Series J funding round, bringing its total funding to $8.6 billion. The round was co-led by Thrive Capital, Andreessen Horowitz, GIC, WCM Investment Management, Insight Partners, and DST Global, with participation from both existing and new investors.

Click here for the original news story.